Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Rating of “Hold” by Analysts
Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) has been assigned an average rating of “Hold” from the seven analysts that are currently covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month target […]
More Stories
Student Loan Delinquencies Soar as Pandemic-Era Protections Expire
By Tom Ozimek Student loan delinquencies spiked in the first quarter of 2025 as the federal government resumed reporting overdue...
Federal Grand Jury Indicts Wisconsin Judge Accused of Helping Illegal Immigrant Evade ICE
By T. J. Muscaro Milwaukee County Circuit Judge Hannah Dugan was indicted by a federal grand jury on May 13,...
Trump Pitches America’s ‘Golden Age’ to Wealthy Gulf Investors
By Emel Akan and Andrew Moran RIYADH, Saudi Arabia—When President Donald Trump arrived in the Saudi capital on May 13,...
US Inflation Slows to Lowest Level Since February 2021
By Andrew Moran The U.S. annual inflation rate eased to its lowest level in more than four years, even as...
Jane Street Group LLC Grows Stake in Gerdau S.A. (NYSE:GGB)
Jane Street Group LLC increased its holdings in Gerdau S.A. (NYSE:GGB – Free Report) by 221.1% during the fourth quarter,...
Amazon.com, Inc. (NASDAQ:AMZN) Position Decreased by First Commonwealth Financial Corp PA
First Commonwealth Financial Corp PA lessened its holdings in Amazon.com, Inc. (NASDAQ:AMZN) by 1.0% during the fourth quarter, Holdings Channel.com...